About: Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $9.00 (-0.83%)
XLO NASDAQ Xilio Development Inc
Xilio Development Inc share price
XLO price activity
Last Price
$9.000
Change (24hr)
-0.08 USD (-0.83%)
Volume
3.05K
Volume (4w avg)
-
Open
$9.05
Day Range
$8.91 - $9.07
Previous Close
$9.08
Last Trade
13 Oct, 4:17 pm GMT+0
Delayed
13 Oct, 4:17 pm GMT+0
XLO price performance
Delayed
13 Oct, 4:17 pm GMT+0
XLO Market Signals